Quick Facts

• Addresses: Vitamin D deficiency and inadequacy.
• Supports: The body’s absorption of calcium and phosphate.
• Helps to manage: Rickets in children and osteomalacia in adults.
• Contributes to: Healthy bone mineralization and development.

---

Vitamin D2, also known as ergocalciferol, is a form of vitamin D administered to support the maintenance of adequate vitamin D status in the body. Its primary therapeutic application is the prevention and management of vitamin D deficiency and insufficiency, conditions that may compromise skeletal health.

The presence of sufficient vitamin D is necessary to promote the absorption of calcium and phosphorus in the gut, which are key minerals for bone health. As a result, Vitamin D2 is utilized in clinical practice to help manage conditions associated with low vitamin D levels, such as rickets (bone softening in children) and osteomalacia (bone softening in adults). By supporting appropriate mineral absorption, the treatment contributes to normal bone mineralization and the maintenance of skeletal integrity.

Beyond bone health, the physiological roles of vitamin D include assisting in promoting general health outcomes by modulating neuromuscular and immune function, and supporting the reduction of inflammation.

Eligibility Map: Who can and cannot use Vitamin D2 (Ergocalciferol) — official regulatory information

Population Status	Eligibility Rule as Stated by Regulators
Contraindicated	Use is strictly prohibited for patients with hypercalcemia (high blood calcium levels), hypervitaminosis D (Vitamin D toxicity), or abnormal sensitivity/allergy to Ergocalciferol or its components.
Restricted Use	Conditional use with close monitoring is required for individuals with impaired renal function, a history of kidney stones (nephrolithiasis), or sarcoidosis. Oral forms are contraindicated in malabsorption syndrome.
Age-Group Use	Use is established across adults, older adults, and pediatric patients for treating deficiency, though dosing must be highly individualized in children due to the narrow therapeutic-to-toxic range.
Maternal Status	Use during pregnancy is not recommended at doses exceeding the Recommended Dietary Allowance (RDA). Caution is required during lactation due to the transfer of Vitamin D into breast milk.

Connection to the overall eligibility profile: Regulatory documents define eligibility primarily by the patient’s existing metabolic status and organ function, strictly prohibiting use in individuals with excessive calcium or Vitamin D levels. Eligibility is established for all ages when treating a deficiency, but conditional use and close monitoring are mandatory for groups with specific constraints, such as impaired renal function or those who are pregnant.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Vitamin D2 (Ergocalciferol), strictly based on regulatory prescribing information. The primary concern in co-administration is the potential for pharmacodynamic reinforcement of high blood calcium levels (hypercalcemia).

---

Documented Interaction Patterns

Interaction Type	Interacting Substances (Examples)	Regulatory Outcome/Constraint
Pharmacodynamic Reinforcement	Thiazide Diuretics (e.g., Hydrochlorothiazide), other Vitamin D Analogs, Calcium/Phosphate Supplements	Additive risk of hypercalcemia; requires caution and monitoring.
Pharmacodynamic (Cardiac Risk)	Digitalis Glycosides (e.g., Digoxin)	Increased risk of cardiac arrhythmias due to hypercalcemia.
Pharmacokinetic (Reduced Absorption)	Bile Acid Sequestrants (e.g., Cholestyramine), Mineral Oil	Reduction in systemic exposure; requires mandatory administration separation by several hours.
Pharmacokinetic (Increased Clearance)	Enzyme Inducers (e.g., Phenytoin, Barbiturates, Rifampicin)	Acceleration of Vitamin D2 metabolism, reducing its systemic concentration.

---

The regulatory profile defines constraints for these combinations. For instance, mandatory timing separation is required when co-administering with Bile Acid Sequestrants to mitigate interference with absorption, while simultaneous use with other Vitamin D metabolites is restricted due to the high risk of additive effects on calcium and phosphate levels.

Nuclear Receptor-Mediated Gene Transcription

Vitamin D2 (ergocalciferol) is a prohormone that undergoes two hydroxylation steps, primarily in the liver and kidney, to become the active metabolite, 1,25-dihydroxyvitamin D2 (ercalcitriol). This active form acts as an agonist through receptor-mediated signaling by binding to the nuclear Vitamin D Receptor (VDR). The VDR-ligand complex modulates the transcription of target genes by binding to Vitamin D Response Elements (VDREs) on the DNA, initiating signaling sequences that lead to downstream effects across various biological systems.

---

Signaling Cascade Effects on Mineral Transport

VDR activation influences molecular processes controlling calcium and phosphorus flux. The active metabolite of vitamin D2 acts on cells in the small intestine, kidney, and bone to influence the absorption, reabsorption, and mobilization of these minerals. This mechanistic cascade determines the systemic concentration profile of calcium and phosphorus.

---

Influence on VDR-Expressing Immune Cell Function

The VDR is expressed in cells of the immune system. The active metabolite engages mechanisms influencing signal transduction patterns by modifying the differentiation, proliferation, and function of these cells. This pathway effect alters cellular activity profiles, influencing the transcription of genes associated with immune responses.

Vitamin D2 (Ergocalciferol) is primarily administered via the oral route, utilizing dosage forms such as capsules, tablets, or a calibrated oral solution. Regional prescribing information may also outline the use of an intramuscular injection for certain clinical scenarios, such as patients with severe malabsorption.

Official usage patterns require dose individualization and distinguish between chronic maintenance and repletion therapy. For chronic conditions like Hypoparathyroidism, regimens typically involve a daily dose range of 50,000 to 200,000 IU, often used concurrently with calcium supplementation. Conversely, for the repletion of severe deficiency, an intermittent schedule is utilized, such as 50,000 IU administered once weekly for a limited duration.

Administration guidelines mandate that Ergocalciferol should be consumed with a meal containing some fat to optimize its absorption, reflecting its status as a fat-soluble compound. The oral liquid form requires precise measurement using the dedicated calibrated dropper provided. Usage protocols emphasize that the dosage must be strictly individualized under close medical supervision. This oversight includes the requirement for frequent monitoring of blood calcium and phosphorus levels to guide any necessary dose adjustments. In the event of a missed dose, standard practice is to skip the missed dose if it is near the next scheduled time.

Vitamin D2: Recent Clinical Evidence

Evidence for Use in Vitamin D Deficiency and Insufficiency

Research primarily utilized short-term randomized controlled trials (RCTs) to examine changes in the blood biomarker 25-hydroxyvitamin D [25(OH)D] in adults and older adults with low Vitamin D levels. Studies report that administration of Vitamin D2 was associated with a measured increase in the concentration of the 25( OH) D biomarker. Findings were mixed when assessing relative effectiveness compared to Vitamin D3, making it challenging to draw broad conclusions about which form is superior for all individuals studied. Furthermore, the long-term durability of these changes is not fully established.

Evidence for Skeletal Health and Mineral Regulation

The research base for skeletal health includes historical clinical trials and observational studies. Vitamin D2 was evaluated in studies concerning bone softening conditions like rickets and osteomalacia. Evidence describes that its use was studied for bone mineralization markers in individuals who had severe deficiency. While its role in mineral balance is foundational, dedicated recent RCTs focusing exclusively on D2 for major skeletal events like fractures are limited, as many long-term studies often combined data from both D2 and D3.

Exploratory Research and Unanswered Questions

Research has explored non-skeletal roles, such as changes in inflammatory markers or cardiovascular health, primarily through small-scale RCTs. Evidence is limited for these extra-skeletal endpoints, as most large trials utilized Vitamin D3. Overall, the evidence landscape highlights significant research gaps, including modest sample sizes and restricted follow-up durations in many trials. Consequently, the clinical relevance of changes in surrogate markers and the data for long-term outcomes remain uncertain across the research base.

Key Studies & References

1. Relative Efficacy of Vitamin D2 and Vitamin D3 in Improving Vitamin D Status: Systematic Review and Meta-Analysis
2. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis
3. Vitamin D Deficiency - StatPearls (for definitions, skeletal context, and historical use)
4. Vitamin D: supplement use in specific population groups (NICE Guideline PH56)

Common questions about Vitamin D2 (FAQ)

Q: What is the difference between Vitamin D2 (Ergocalciferol) and Vitamin D3 (Cholecalciferol)?

Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol) are chemically different forms. Regulatory documents and official sources note that D3 is chemically similar to the form the body naturally produces, with some studies reporting that D3 may be more effective than D2 at raising the concentration of the circulating vitamin D biomarker, although overall evidence is mixed.

Q: What are the main conditions that Vitamin D2 is approved to treat?

According to official FDA prescribing information, Vitamin D2 is indicated for specific conditions. These include treating hypoparathyroidism (a condition where the body does not make enough parathyroid hormone), refractory rickets (a form of rickets resistant to standard treatments), and familial hypophosphatemia (low phosphate levels that run in families).

Q: How is Vitamin D2 deficiency typically diagnosed?

Vitamin D status is typically evaluated by measuring the concentration of a specific marker in the blood called 25-hydroxyvitamin D (25( OH) D). Official medical guidance generally defines deficiency as a serum level of 25( OH) D below 20 ng/ml. This measurement is used as a standard practice to assess a patient’s vitamin D status.

Q: Can Vitamin D2 be taken by children or adolescents?

Yes, official regulatory documents state that use is established across pediatric patients for treating deficiency. However, the drug’s use in children requires highly individualized dosing and close supervision by a healthcare professional due to the narrow therapeutic range.

Q: Can individuals with liver problems use Vitamin D2?

Official information notes that the first necessary step for vitamin D activation occurs in the liver. Therefore, liver (hepatic) impairment can alter how the drug is metabolized and its therapeutic activity. Additionally, decreased bile due to liver dysfunction may affect the oral absorption of Vitamin D2.

Q: Does Vitamin D2 interact with cholesterol-lowering drugs (statins)?

While regulatory labels do not always list a major interaction with all statins (a common class of cholesterol-lowering drugs), some evidence indicates that Vitamin D and these drugs may be metabolized by the same liver enzyme. This situation could potentially alter the concentration of both medicines in the body.

Q: Can Vitamin D2 affect blood pressure readings?

Official labeling lists hypertension (high blood pressure) as a potential adverse reaction. This is noted particularly as a symptom of hypervitaminosis D (vitamin D toxicity) that can occur if calcium levels become too high, which can impair kidney function.

Q: How quickly should I expect to see an effect after starting Vitamin D2?

Regulatory documents indicate that there is a time lag of 10 to 24 hours between administration and when the drug's action begins, due to the time needed for activation in the body. Clinical evidence shows that achieving adequate blood levels (the 25( OH) D concentration) generally takes one to three months of supplementation.

Q: Why do some people need to take Vitamin D2 for long periods?

Vitamin D2 is approved for the treatment of chronic metabolic conditions, such as hypoparathyroidism and familial hypophosphatemia. These conditions often require long-term maintenance therapy to continuously regulate the essential balance of calcium and phosphorus in the body.

Q: Do foods high in calcium affect how Vitamin D2 works?

Official documentation notes that adequate dietary calcium is required for the medicine to work effectively. However, due to the primary risk of hypercalcemia (excessive calcium in the blood), an excessive intake of calcium is a safety concern mentioned in official warnings.

Q: Is there scientific research that supports the use of Vitamin D2 for preventing certain diseases?

Official medical policy sources and major institutional guidelines indicate that while low vitamin D levels have been associated with increased risk of certain diseases, no official institutional guidelines currently recommend vitamin D supplementation specifically for the purpose of disease prevention.

Q: Are there any known interactions between Vitamin D2 and herbal supplements like St. John's wort?

Official drug safety information advises that patients inform their healthcare provider about all other medications, including vitamins and herbs, when starting Vitamin D2. The purpose of this advisory is to ensure the healthcare provider has complete information to assess potential risks, as specific herbal interactions may not be explicitly named on the label.

Q: What is the half-life of Vitamin D2 in the body?

The biologically active metabolite of Vitamin D2, 1,25-dihydroxyvitamin D, has a relatively short circulating half-life of approximately 4 to 15 hours. The storage form, 25-hydroxyvitamin D, which is the primary marker doctors measure, has a much longer half-life of approximately 15 days to 2–3 weeks.

Q: Does taking Vitamin D2 affect results on blood tests other than calcium?

While monitoring blood calcium and phosphorus is required, official documents list side effects related to toxicity that can affect other blood test results. These include effects on the metabolic system, such as anemia, and signs of kidney (renal) impairment, such as reversible azotemia.

Q: What evidence exists regarding Vitamin D2's role in immune function?

The drug's mechanism of action states that the active metabolite binds to receptors found in immune cells. Exploratory research suggests that Vitamin D may play a role in immune function, for instance, by promoting the expression of certain antimicrobial peptides in immune cells.

Q: Can Vitamin D2 cause allergic reactions?

Official product information notes that the medicine is contraindicated in patients with an abnormal sensitivity or known allergy to its components. Additionally, the label for some specific formulations notes that certain color additives, such as a yellow dye (tartrazine), may cause allergic reactions in susceptible patients.

Q: Are there specific dietary restrictions mentioned in official documents for people taking Vitamin D2?

Official information advises that the prescribing physician may need to adjust the patient's dietary intake of foods containing natural or added calcium and phosphate. The purpose of this adjustment is to support the maintenance of mineral balance and reduce the potential risk of toxicity.

Storage and Disposal of Vitamin D2 (Ergocalciferol)

Vitamin D2 must be stored under specific, controlled conditions to maintain its effectiveness. Regulatory labeling requires storage at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from light and moisture. The medicine must remain in its original, tightly closed container and should not be frozen.

For safety, the product must be kept strictly out of the sight and reach of children.

Disposal of unused or expired Ergocalciferol must follow official guidance. The product should generally not be disposed of in household trash or wastewater. Disposal should be completed according to local regulations, preferably utilizing authorized medicine take-back programs where available.